May 21, 2018
While the dice are rolled, the IBB (+0.61%) is jumping – the hand is hot yet the table is cold
As technicals, fundamentals and momentum seem “pushed” to a current optimism
Pre-open indications: 2 BUYs
Last week’s indication prediction review: 13 HITs and 7 miss (3 by pennies)
If you were a subscriber, and read Friday’s closing “brief” you’d understand how today’s indications shed light on share pricing!
Get set for a 200 point jump as a trade war is put “on hold” …
May 17, 2018
Q1/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies.
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
May 21, 2018
… Started slipping at 11 a.m. to closed negative of the 45 covered
Initial sector strength became a liability after Friday’s barely negative close
As the upside was weak (range of +$0.01 to $0.48) while the downside ranged (-$0.01 to -$3.62) seeing larger amounts
Pre-open indications: 1 HIT and 1 MISS
Out and about: uniQure N.V. (QURE) presented new data demonstrating clinical benefit in Hemophilia B patients with pre-existing Anti-AAV5 Neutralizing Antibodies and closed up +$0.19
We keep you informed, if you want to be knowledgeable of the “bones” of the sector - be a subscriber to understand what you need to do in tomorrow’s market. Let the “numbers” speak since sentiment is capricious!
April 23, 2018
PSTI closed Friday at $1.20 (-$0.04) and is UP +$0.04 in the pre-market The 5-year joint project was granted $2.5 million from the U.S. NIH
April 16, 2018
Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09 ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).
April 12, 2018
ONVO closed down -$0.01 to $1.01 and is UP +$0.04 or +$0.04 or +3.96 These new data points provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.